Literature DB >> 33386152

Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.

Hongxia Ma1, Qian Zhang1, Qianqian Duan2, Qin Zhang2, Fengsen Li3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33386152     DOI： 10.1016/j.lungcan.2020.12.015

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  1 in total

1.  Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion.

Authors:  Shuli Wei; Mangsha Hu; Yan Yang; Xiaojie Huang; Baizhou Li; Liren Ding; Pingli Wang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.